Abstract：In recent years, nonalcoholic fatty liver disease (NAFLD) has increased because of the growing prevalence of obesity and overweight in the pediatric population. It has become the most common form of chronic liver diseases in children and the related research on NAFLD is expanded. The "two-hit" and "multiple hit" hypothesis have been widely accepted, and some research has shown that genetic, diet structure and environmental factors appear to play a crucial role in the development of pediatric NAFLD. Though it is expected by researchers, there is not an available satisfactory noninvasive marker for the diagnosis of this disease. Fortunately, some new non-invasive prediction scores for pediatric NAFLD have been developed. There is currently no established special therapy, and lifestyle intervention should be adequate for most cases of NAFLD in children. This article reviews the advances in the current knowledge and ideas concerning pediatric NAFLD, and discusses the diagnosis, perspective therapies and scoring methods for this disease.
Harrison SA, Kadakia S, Lang KA, et al. Nonalcoholic steatohepatitis: what we know in the new millennium[J]. Am J Gastroenterol, 2002, 97(11): 2714-2724.
[4]
Alisi A, Manco M, Vania A, et al. Pediatric nonalcoholic fatty liver disease in 2009[J]. J Pediatr, 2009, 155(4): 469-474.
[5]
Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights[J]. J Hepatol, 2013, 58(6): 1218-1229.
Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents[J]. Pediatrics, 2006, 118(4): 1388-1393.
[8]
Pacifico L, Poggiogalle E, Cantisani V, et al. Pediatric nonalcoholic fatty liver disease: a clinical and laboratory challenge[J]. World J Hepatol, 2010, 2(7): 275-288.
Nobili V, Bedogni G, Berni CR, et al. The potential role of fatty liver in paediatric metabolic syndrome: a distinct phenotype with high metabolic risk?[J]. Pediatr Obes, 2012, 7(6): e75-e80.
Mager DR, Patterson C, So S, et al. Dietary and physical activity patterns in children with fatty liver[J]. Eur J Clin Nutr, 2010, 64(6): 628-635.
[13]
Alisi A, Cianfarani S, Manco M, et al. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment[J]. Ann Med, 2012, 44(1): 29-40.
[14]
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years[J]. Gut, 2009, 58(11): 1538-1544.
[15]
Valenti L, Motta BM, Alisi A, et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease[J]. J Pediatr Gastroenterol Nutr, 2012, 54(5): 588-593.
[16]
Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease[J]. Hepatology, 2010, 52(4): 1274-1280.
[17]
Lin YC, Chang PF, Chang MH, et al. A common variant in the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene is associated with nonalcoholic fatty liver disease in obese children[J]. Am J Clin Nutr, 2013, 97(2): 326-331.
[18]
Adams LA, White SW, Marsh JA, et al. Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57(2): 590-600.
[19]
Rossi F, Bellini G, Alisi A, et al. Cannabinoid receptor type 2 functional variant influences liver damage in children with nonalcoholic fatty liver disease[J]. PLoS One, 2012, 7(8): e42259.
[20]
Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies[J]. J Hepatol, 2012, 56(2): 448-454.
[21]
Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents[J]. Hepatology, 2012, 55(3): 781-789.
[22]
Jin R, Le NA, Liu S, et al. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD[J]. J Clin Endocrinol Metab, 2012, 97(7): E1088-E1098.
[23]
Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease[J]. J Nutr Biochem, 2012, 23(3): 203-208.
[24]
Papandreou D, Karabouta Z, Rousso I. Are dietary cholesterol intake and serum cholesterol levels related to nonalcoholic Fatty liver disease in obese children?[J]. Cholesterol, 2012, 2012: 572820.
[25]
Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol[J]. Scand J Gastroenterol, 2009, 44(4): 471-477.
[26]
Fowden AL, Giussani DA, Forhead AJ. Intrauterine programming of physiological systems: causes and consequences[J]. Physiology(Bethesda), 2006, 21: 29-37.
[27]
Nobili V, Marcellini M, Marchesini G, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children[J]. Diabetes Care, 2007, 30(10): 2638-2640.
[28]
Alisi A, Panera N, Agostoni C, et al. Intrauterine growth retardation and nonalcoholic Fatty liver disease in children[J]. Int J Endocrinol, 2011, 2011: 269853.
[29]
Nobili V, Bedogni G, Alisi A, et al. A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease[J]. Arch Dis Child, 2009, 94(10): 801-805.
[30]
Day CP, James OF. Steatohepatitis: a tale of two "hits"?[J]. Gastroenterology, 1998, 114(4): 842-845.
Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children[J]. Curr Opin Clin Nutr Metab Care, 2010, 13(4): 397-402.
[33]
Portincasa P, Grattagliano I, Palmieri VO, et al. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management[J]. Clin Biochem, 2005, 38(3): 203-217.
[34]
Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children[J]. Arch Dis Child, 2004, 89(7): 648-652.
[35]
Frasinariu OE, Ceccarelli S, Alisi A, et al. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies[J]. Dig Liver Dis, 2013, 45(7): 543-551.
[36]
Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children[J]. J Pediatr Gastroenterol Nutr, 2010, 50(6): 645-649.
[37]
De Vito R, Alisi A, Masotti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease[J]. Int J Mol Med, 2012, 30(1): 49-56.
[38]
Nobili V, Carpino G, Alisi A, et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease[J]. Hepatology, 2012, 56(6): 2142-2153.
[39]
Torres DM, Harrison SA. Hepatic progenitor cells: another piece in the nonalcoholic fatty liver disease puzzle[J]. Hepatology, 2012, 56(6): 2013-2015.
[40]
Swiderska-Syn M, Suzuki A, Guy CD, et al. Hedgehog pathway and pediatric nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57(5): 1814-1825.
[41]
Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach[J]. Nat Rev Gastroenterol Hepatol, 2012, 9(3): 152-161.
[42]
Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease[J]. Hepatology, 2005, 42(3): 641-649.
[43]
Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2010, 16(42): 5286-5296.
[44]
Alisi A, Bedogni G, De Vito R, et al. Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease[J]. Dig Liver Dis, 2011, 43(2): 143-146.
[45]
Patton HM, Lavine JE, Van Natta ML, et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis[J]. Gastroenterology, 2008, 135(6): 1961-1971.
[46]
Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee[J]. J Pediatr Gastroenterol Nutr, 2012, 54(5): 700-713.
[47]
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6): 2005-2023.
[48]
Brunt EM, Janney CG, Di BAM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions[J]. Am J Gastroenterol, 1999, 94(9): 2467-2474.
[49]
Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease[J]. BMC Med, 2009, 7: 21.
[50]
Alkhouri N, De Vito R, Alisi A, et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease[J]. J Hepatol, 2012, 57(6): 1312-1318.
[51]
Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study[J]. Hepatology, 2009, 50(4): 1072-1078.
[52]
Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments[J]. Nutrition, 2012, 28(7-8): 722-726.
[53]
Nobili V, Manco M, Ciampalini P, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study[J]. Clin Ther, 2008, 30(6): 1168-1176.
[54]
Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial[J]. JAMA, 2011, 305(16): 1659-1668.
[55]
Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children[J]. J Pediatr, 2000, 136(6): 739-743.
